查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1675414

2025 年至 2033 年肺癌治療市場報告（按療法、癌症類型（非小細胞肺癌、小細胞肺癌）、配銷通路和地區分類）

Lung Cancer Therapeutics Market Report by Therapy, Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer ), Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

2024IMARC Group全球肺癌治療市場規模達到 330.61 億美元。隨著肺癌發病率的快速上升（全球吸煙和環境污染加劇了肺癌的發病率），個人化治療（包括基於基因圖譜的治療）的進一步發展，以及疾病診斷技術的不斷進步，以確保早期發現病理，推動了市場穩步成長。

肺癌治療市場分析：

主要市場促進因素：全球肺癌的盛行率和死亡率極高，導致肺癌治療市場需求旺盛。

主要市場趨勢：隨著越來越多針對腫瘤細胞特定基因突變的治療方法的出現，市場將朝著個人化醫療的方向發展。此外，在診斷過程中加入人工智慧和機器學習，可以提高獲得此類治療的機會和準確性，這是肺癌治療市場的主要趨勢之一。

地理趨勢：市場分析表明，由於強大的醫療保健結構、醫療支出以及早期使用先進的腫瘤治療方法，北美在肺癌治療市場中處於領先地位。包括中國和印度在內的亞太地區正憑藉快速成長的醫療保健意識和不斷改善的醫療保健服務系統推動市場發展。

競爭格局：根據肺癌治療市場概況，由於知名製藥巨頭和新興生物公司的存在，市場競爭激烈。此外，各大公司正在透過研發和合作來創新和擴大其產品線。

挑戰與機會：新型抗癌藥物的高成本成為肺癌治療向中低收入經濟體推廣的主要挑戰，造成了藥物可近性的差距。然而，隨著肺癌治療市場近期出現開發具有成本效益的學名藥和生物相似藥的機會，這些挑戰也隨之加劇。

肺癌治療市場趨勢：

全球肺癌發生率上升

推動肺癌治療市場成長的另一個因素是肺癌發生率的增加。美國癌症協會對2024年美國肺癌的預測是，新發癌症人數約為234,580人，其中男性116,310人，女性118,270人。死亡人數將達125,070人，其中男性死亡65,790人，女性死亡59,280人。全球人口呈指數級成長，吸煙、空氣和環境污染以及有害的工作場所事件等導致肺癌的有害因素的普遍存在，都證明了這一點。因此，這也影響了肺癌治療市場的統計數據。由於肺癌發生率不斷上升，需要採取更積極的措施。因此，肺癌治療方法，包括藥物的開發和改進也在不斷發展。供應的增加為製藥公司進行了測試、開發新產品並擴大產品類型提供了更多理由。因此，對更有效藥物的需求日益成長。因此，肺癌治療是成長最快的。

個人化醫療的創新

隨著根據基因特徵對每位患者進行治療的個人化醫療的發展，肺癌治療市場成長顯著。近年來，製藥業已經開發並生產出精準攻擊此類突變的藥物。事實證明，這些療法比化療更有效，副作用更少。肺癌治療市場預測顯示個人化醫療將成為該腫瘤治療的基礎；這意味著治療效率的提高，因為處方將更加準確。此外，診斷技術的進步和對影響肺癌進展的遺傳因素的了解不斷加深，推動了人們對精準醫療的日益重視。因此，製藥業對個人化解決方案的投資不斷擴大，使藥物開發與特定患者的需求相結合，並大大推動肺癌治療市場的發展。

診斷和治療不斷進步

技術創新推動市場發展，特別是在診斷和治療領域。此外，改進的影像和人工智慧輔助診斷工具可以更早、更準確地發現肺癌。除此之外，這項理念也將徹底改變治療效果和患者復原。除此之外，肺癌治療市場最近的發展包括引入新的和正在發展的微創手術技術、增強的放射治療方法和先進的藥物傳輸系統，包括基於奈米粒子的化療製劑。此外，先進技術的準確性和有效性無法想像舒適的治療和可恢復的患者視野。此外，所有這些技術的結合正在創造積極的市場前景。

肺癌治療市場細分：

治療性分手：

  • 標靶治療
  • 貝伐單抗
  • 達拉非尼/曲美替尼
  • 鹽酸厄洛替尼
  • 奧希替尼
  • 其他
  • 免疫療法
  • 度伐利尤單抗
  • 納武單抗
  • 阿替利珠單抗
  • 帕博利珠單抗
  • 放射治療
  • 外部光束
  • 內部樑
  • 系統性
  • 化療

標靶治療佔據大部分市場佔有率

由於與傳統化療相比，治療效率更高、副作用更少，因此是最大的細分市場。其中包括能夠準確識別和殺死癌細胞的藥物或其他物質。這種治療方法可能針對的是區分癌細胞與其他細胞的分子和遺傳特徵。此外，目前對肺癌遺傳的理解程度使得我們能夠識別許多特定的分子靶點，並相應地識別出可以阻止這些標靶活化的藥劑。根據肺癌治療市場預測，分子生物學和遺傳學的發展將不斷增加可用於對抗疾病的標靶和藥物的數量。因此，可以合理地假設，由於新的潛在標靶和藥物的出現，標靶治療領域將繼續發展。

癌症分手類型：

  • 非小細胞肺癌（NSCLC）
  • 小細胞肺癌 (SCLC)

非小細胞肺癌（NSCLC）佔據業界最大佔有率

非小細胞肺癌因其發病率高而佔據市場最大佔有率。各個亞型單獨來看具有共同的病理變異，但它們的進展比小細胞肺癌慢。因此，全球 NSCLC 的高盛行率使得不同亞型的肺癌治療市場需求龐大，從而激勵製藥公司和研究人員專注於開發能夠有效治療亞型基因和分子差異的療法和免疫療法。此外，NSCLC分子發病機制不斷變化也確保了精準醫療的發展使NSCLC與市場具有相關性。

依配銷通路分類：

  • 醫院藥房
  • 零售藥局
  • 網路藥局
  • 其他

醫院藥房是主要的細分市場

由於肺癌治療的複雜性和先進性，醫院藥局是肺癌治療領域最大的通路。醫生需要在受控環境中進行治療，包括化療方案，這些治療需要嚴格調控以避免副作用。根據肺癌治療市場分析，大多數肺癌治療都是針對住院患者，因為需要化療、標靶治療和免疫療法等複雜療法。此外，醫院藥局對於促進肺癌綜合治療至關重要，因為患者可以立即獲得所有所需的治療，並且在同一家可以協調腫瘤科、外科和放射科的醫院獲得治療。除此之外，中心化的集中化確保患者在接受治療時延遲最少，進而提高治療的效果。此外，對基礎設施和人員專業知識的需求正在增加肺癌治療市場的收入。

按地區分類：

  • 北美洲
  • 美國
  • 加拿大
  • 亞太
  • 中國
  • 日本
  • 印度
  • 韓國
  • 澳洲
  • 印尼
  • 其他
  • 歐洲
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他
  • 拉丁美洲
  • 巴西
  • 墨西哥
  • 其他
  • 中東和非洲

北美引領市場，佔據肺癌治療藥物最大的市場佔有率

該報告還對所有主要區域市場進行了全面的分析，包括北美（美國和加拿大）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。根據報告，北美是肺癌治療最大的區域市場。

由於疾病盛行率高、醫療保健基礎設施先進以及醫療保健支出最高的因素之一，北美擁有最大的區域肺癌治療市場佔有率。除此之外，美國和歐元區國家在研發上投入的高額政府投入和私部門支持也在北美市場的成長中扮演關鍵角色。此外，對開發肺癌診斷和治療技術和措施的投資不斷加速，對肺癌治療市場的收入產生了積極影響。正如肺癌治療市場的成長趨勢所示，在過去的十年中，各種標靶療法和免疫療法已經被開發並用於治療肺癌。此外，該地區的監管環境也對抗癌藥物採取了快速核准的友善政策。此外，該地區患者的高認知度和保險覆蓋率確保北美繼續主導全球市場。

競爭格局：

市場研究報告也對市場競爭格局進行了全面的分析。也提供了所有主要公司的詳細資料。肺癌治療行業的一些主要市場參與者包括：

  • 艾伯維公司（AbbVie Inc.）
  • 安進公司
  • 阿斯特捷利康公司
  • 勃林格殷格翰國際股份有限公司
  • 百時美施貴寶公司
  • 第一三共株式會社
  • 禮來公司
  • 葛蘭素史克公司
  • 默克公司
  • 諾華公司
  • 輝瑞公司
  • 羅氏控股公司
  • 武田藥品工業株式會社

本報告回答的關鍵問題：

  • 全球肺癌治療市場迄今表現如何？
  • 全球肺癌治療市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對全球肺癌治療市場有何影響？
  • 主要的區域市場有哪些？
  • 哪些國家擁有最具吸引力的肺癌治療市場？
  • 根據治療方法，市場區隔如何？
  • 肺癌治療市面上哪種療法最具吸引力？
  • 根據癌症類型，市場分佈如何？
  • 肺癌治療市場上最具吸引力的癌症類型是哪一種？
  • 根據配銷通路，市場如何分類？
  • 肺癌治療市場中最具吸引力的配銷通路是哪一個？
  • 市場的競爭格局是怎麼樣的？
  • 全球肺癌治療市場的關鍵參與者/公司有哪些？

本報告回答的關鍵問題：

  • 全球肺癌治療市場迄今表現如何？
  • 全球肺癌治療市場的促進因素、限制因素和機會是什麼？
  • 每個促進因素、限制因素和機會對全球肺癌治療市場有何影響？
  • 主要的區域市場有哪些？
  • 哪些國家擁有最具吸引力的肺癌治療市場？
  • 根據治療方法，市場區隔如何？
  • 肺癌治療市面上哪種療法最具吸引力？
  • 根據癌症類型，市場分佈如何？
  • 肺癌治療市場上最具吸引力的癌症類型是哪一種？
  • 根據配銷通路，市場如何分類？
  • 肺癌治療市場中最具吸引力的配銷通路是哪一個？
  • 市場的競爭格局是怎麼樣的？
  • 全球肺癌治療市場的關鍵參與者/公司有哪些？

目錄

第 1 章：前言

第 2 章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第5章：全球肺癌治療市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依療法

  • 標靶治療
    • 關鍵部分
      • 貝伐單抗
      • 達拉非尼/曲美替尼
      • 鹽酸厄洛替尼
      • 奧希替尼
      • 其他
  • 免疫療法
    • 關鍵部分
      • 度伐利尤單抗
      • 納武單抗
      • 阿替利珠單抗
      • 帕博利珠單抗
  • 放射治療
    • 關鍵部分
      • 外部光束
      • 內部樑
      • 系統性
  • 化療

第 7 章：市場區隔：按癌症類型

  • 非小細胞肺癌（NSCLC）
  • 小細胞肺癌 (SCLC)

第 8 章：市場區隔：按配銷通路

  • 醫院藥房
  • 零售藥局
  • 網路藥局
  • 其他

第9章：市場細分：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場區隔：依國家

第 10 章：促進因素、限制因素與機遇

  • 概述
  • 驅動程式
  • 限制
  • 機會

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第 14 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca Plc
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company Limited
    • Eli Lilly and Company
    • GSK PLC
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Roche Holding AG
    • Takeda Pharmaceutical Company Limited
Product Code: SR112025A8336

The global lung cancer therapeutics market size reached USD 33,061.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 72,610.7 Million by 2033, exhibiting a growth rate (CAGR) of 9.14% during 2025-2033. The market is experiencing steady growth driven by the rapid increase in the incidence of lung cancer, which is aggravated by smoking and environmental pollution around the world, the further development of individualized treatment, including based on the gene profile, and the continuous advancement of technology for diagnosing the disease, to ensure early detection of the pathology.

Lung Cancer Therapeutics Market Analysis:

Major Market Drivers: The massive prevalence and mortality associated with lung cancer worldwide is creating a high lung cancer therapeutics market demand.

Key Market Trends: The market will develop in the direction of personalized medicine as an increasing number of therapies addressing particular genetic mutations in tumor cells are created. Additionally, the incorporation of AI and machine learning in the diagnostic processes enhancing the chances and precision of accessing such treatments is acting as one of the major lung cancer therapeutics market trends.

Geographical Trends: The market analysis states that North America leads the market regarding lung cancer therapeutics due to the robust healthcare structures, health expenditures, and early use of advanced oncology treatments. Asia Pacific region, including China and India, is driving the market based on rapidly growing healthcare awareness and improved healthcare delivery systems.

Competitive Landscape: According to the lung cancer therapeutics market overview, the market is highly competitive based on the existence of well-established pharmaceutical giants and new emerging biofirms. Additionally, major companies are innovating and expanding their product lines through research and development and partnerships.

Challenges and Opportunities: The high cost of new cancer medicines emerges as the main challenge to the lung cancer therapeutics revelations to the low- and middle-income economies, creating accessibility gaps. However, such challenges amplify as lung cancer therapeutics market recent opportunities for developing cost-effective generics and biosimilars.

Lung Cancer Therapeutics Market Trends:

Rising incidence of lung cancer worldwide

Another factor contributing to the lung cancer therapeutics market growth is the increasing incidence of lung cancer. The American Cancer Society made an estimation of lung cancer in the US by 2024. The number of new cancer occurrences should approximately equal 234,580 individuals, including 116,310 males and 118,270 females. The number of deaths will equal 125,070 deaths, which involves 65,790 male deaths and 59,280 female deaths. This can be supported by the exponentially growing global population and the prevalence of harmful factors causing lung cancer such as smoking, air and environmental pollution, and harmful workplace events. Thus, this is also influencing the lung cancer therapeutics market statistics. Due to the constantly increasing incidence of lung cancer, more active measures are needed. Accordingly, the development and improvement of methods, including drugs, for lung cancer treatment are constantly developing. Increased supply creates more reason for pharmaceutical companies to conduct tests and develop new ones and expand their assortment. Accordingly, demand for more effective drugs is growing. Thus, lung cancer therapeutics is the fastest-growing.

Innovations in personalized medicine

The lung cancer therapeutics market growth is increasing significantly with the development of personalized medicine, which treats each patient based on genetic features. In recent years, the drug industry has developed and produced drugs that precisely attack such mutations. These have proven to be more effective than chemotherapy, causing fewer side effects. The lung cancer therapeutics market forecast suggests that personalized medicine will become the basis of therapy for this oncology; this means an increase in the efficiency of therapy since the prescription will be more accurate. Furthermore, the growing emphasis on precision medicine is fueled by technological progress in diagnostics and an increased understanding of genetic factors influencing lung cancer progression. Consequently, the pharmaceutical industry's investment in personalized solutions continues to expand, aligning drug development with specific patient needs and substantially driving the lung cancer therapeutics market forward.

Continuous advancements in diagnostics and treatment

Technological innovations drive the market, particularly in diagnostics and treatment delivery. In addition, improved imaging and AI-assisted diagnostic tools allow lung cancer detection early and more accurately. Along with this, this notion is a game-changer for treatment efficacy and patient recovery. Apart from this, the lung cancer therapeutics market recent developments include the introduction of new and developing minimally invasive surgery techniques, enhanced radiation treatment approaches, and advanced drug-delivery systems, including nanoparticle-based chemo preparations. In addition, the accuracy and effectiveness of advanced technology cannot imagine a comfortable treatment and recoverable patient view. Furthermore, the combination of all these technologies is creating a positive market outlook.

Lung Cancer Therapeutics Market Segmentation:

Breakup by Therapy:

  • Targeted Therapy
  • Bevacizumab
  • Dabrafenib/Trametinib
  • Erlotinib Hydrochloride
  • Osimertinib
  • Others
  • Immunotherapy
  • Durvalumab
  • Nivolumab
  • Atezolizumab
  • Pembrolizumab
  • Radiation Therapy
  • External Beam
  • Internal Beam
  • Systemic
  • Chemotherapy

Targeted therapy accounts for the majority of the market share

The therapy segment is the largest as it is more efficient and has fewer side effects compared to traditional chemotherapy. It includes drugs or other materials that can accurately recognize and kill cancer cells. This treatment is probably directed at the molecular and genetic features that differentiate cancer cells from others. In addition, the current level of understanding of genetic aspects of lung cancer allows the identification of many specific molecular targets and, correspondingly, agents that can prevent the activation of these targets. According to the lung cancer therapeutics market forecast, the development of molecular biology and genetics will consistently increase the number of targets and agents that could be used to combat the described disease. Hence, it is reasonable to suppose that the targeted therapy segment will continue developing due to the appearance of new potential targets and agents.

Breakup by Cancer Type:

  • Non-Small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer (SCLC)

Non-Small Cell Lung Cancer (NSCLC) holds the largest share of the industry

The non-small cell lung cancer segment holds the largest share in the market due to its high prevalence. Individually, the subtypes share pathological variations, but they progress more slowly than small-cell lung cancer. As such, the high global prevalence of NSCLC creates a sizable lung cancer therapeutics market demand for the different subtypes, thereby incentivizing pharmaceutical companies and researchers to focus on developing therapies and immunotherapies that can treat the subtype gene and molecular distinctions effectively. In addition, the changing molecular pathogenesis capacity for NSCLC also ensures that the development of precision medicine causes NSCLC to have a correlation with the market.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other

Hospital pharmacies represents the leading market segment

Hospital pharmacies are the largest channel of distribution in the lung cancer therapeutics segment due to the complicated and advanced nature of the therapies for the disease. Doctors require a controlled environment to administer treatments, including chemotherapy solutions, which need to be carefully regulated to avoid side effects. According to the lung cancer therapeutics market analysis, most lung cancer therapies are for inpatients given the need for complex therapies such as chemotherapy, targeted therapy, and immunotherapies According to the lung cancer therapeutics market analysis, most lung cancer therapies are for inpatients given the need for complex therapies such as chemotherapy, targeted therapy, and immunotherapies. Additionally, hospital pharmacies are critical in facilitating integrated lung cancer care as the patient can access all the required treatments immediately and from the same hospital that can coordinate oncology, surgery, and radiology departments. Apart from this, the centralization of centrality ensures the patient undergoes therapy with minimal delays which improves the effectiveness of the therapeutics. Furthermore, the demand for infrastructure and personnel expertise is increasing the lung cancer therapeutics market revenue.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America leads the market, accounting for the largest lung cancer therapeutics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for lung cancer therapeutics.

North America has the largest regional lung cancer therapeutics market share due to high disease prevalence, advanced healthcare infrastructure, and one of the highest healthcare spender factors. Along with this, high government contribution and private sector support in the US and Eurozone countries, spent on research and development, also play a key role in the growth of the North American market. Furthermore, the accelerating investments to develop technologies and initiatives to diagnose and treat lung cancer are influencing lung cancer therapeutics market revenue positively. As the lung cancer therapeutics market growth trend shows, in the past decade, various targeted therapies and immunotherapies have been developed and used in the treatment of lung cancer. Furthermore, the regulatory environment across the region also has a friendly policy of fast-track cancer drugs. Moreover, the high levels of patient awareness across the region, and insurance coverage ensures North America continues to dictate the global market.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the lung cancer therapeutics industry include:

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • GSK PLC
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Takeda Pharmaceutical Company Limited

Key Questions Answered in This Report:

  • How has the global lung cancer therapeutics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global lung cancer therapeutics market?
  • What is the impact of each driver, restraint, and opportunity on the global lung cancer therapeutics market?
  • What are the key regional markets?
  • Which countries represent the most attractive lung cancer therapeutics market?
  • What is the breakup of the market based on the therapy?
  • Which is the most attractive therapy in the lung cancer therapeutics market?
  • What is the breakup of the market based on the cancer type?
  • Which is the most attractive cancer type in the lung cancer therapeutics market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the lung cancer therapeutics market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global lung cancer therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Lung Cancer Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy

  • 6.1 Targeted Therapy
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Bevacizumab
      • 6.1.2.2 Dabrafenib/Trametinib
      • 6.1.2.3 Erlotinib Hydrochloride
      • 6.1.2.4 Osimertinib
      • 6.1.2.4 Others
    • 6.1.2 Market Forecast
  • 6.2 Immunotherapy
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Durvalumab
      • 6.2.2.2 Nivolumab
      • 6.2.2.3 Atezolizumab
      • 6.2.2.4 Pembrolizumab
    • 6.2.2 Market Forecast
  • 6.3 Radiation Therapy
    • 6.3.1 Market Trends
    • 6.3.2 Key Segment
      • 6.3.2.1 External Beam
      • 6.3.2.2 Internal Beam
      • 6.3.2.3 Systemic
    • 6.3.2 Market Forecast
  • 6.4 Chemotherapy
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Cancer Type

  • 7.1 Non-small Cell Lung Cancer (NSCLC)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Small Cell Lung Cancer (SCLC)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Amgen Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 AstraZeneca Plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Boehringer Ingelheim International GmbH
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Bristol-Myers Squibb Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Daiichi Sankyo Company Limited
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Eli Lilly and Company
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 GSK PLC
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Merck & Co. Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Novartis AG
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Pfizer Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
    • 14.3.12 Roche Holding AG
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
    • 14.3.13 Takeda Pharmaceutical Company Limited
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Lung Cancer Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019-2024
  • Figure 3: Global: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 4: Global: Lung Cancer Therapeutics Market: Breakup by Therapy (in %), 2024
  • Figure 5: Global: Lung Cancer Therapeutics Market: Breakup by Cancer Type (in %), 2024
  • Figure 6: Global: Lung Cancer Therapeutics Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Lung Cancer Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Lung Cancer Therapeutics (Targeted Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Lung Cancer Therapeutics (Targeted Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Lung Cancer Therapeutics (Immunotherapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Lung Cancer Therapeutics (Immunotherapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Lung Cancer Therapeutics (Radiation Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Lung Cancer Therapeutics (Radiation Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Lung Cancer Therapeutics (Chemotherapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Lung Cancer Therapeutics (Chemotherapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Lung Cancer Therapeutics (Non-small Cell Lung Cancer (NSCLC)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Lung Cancer Therapeutics (Non-small Cell Lung Cancer (NSCLC)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Lung Cancer Therapeutics (Small Cell Lung Cancer (SCLC)) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Lung Cancer Therapeutics (Small Cell Lung Cancer (SCLC)) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Lung Cancer Therapeutics (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Lung Cancer Therapeutics (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Lung Cancer Therapeutics (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Lung Cancer Therapeutics (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Lung Cancer Therapeutics (Online Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Lung Cancer Therapeutics (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Lung Cancer Therapeutics (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Lung Cancer Therapeutics (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: North America: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: North America: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: United States: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: United States: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Canada: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Canada: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Asia-Pacific: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Asia-Pacific: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: China: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: China: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Japan: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Japan: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: India: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: India: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: South Korea: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: South Korea: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Australia: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Australia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Indonesia: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Indonesia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Others: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Europe: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Europe: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Germany: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Germany: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: France: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: France: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: United Kingdom: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: United Kingdom: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Italy: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Italy: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Spain: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Spain: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Russia: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Russia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Others: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Latin America: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Latin America: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Brazil: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Brazil: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Mexico: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Mexico: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Others: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Middle East and Africa: Lung Cancer Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Middle East and Africa: Lung Cancer Therapeutics Market: Breakup by Country (in %), 2024
  • Figure 76: Middle East and Africa: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Global: Lung Cancer Therapeutics Industry: Drivers, Restraints, and Opportunities
  • Figure 78: Global: Lung Cancer Therapeutics Industry: Value Chain Analysis
  • Figure 79: Global: Lung Cancer Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Lung Cancer Therapeutics Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Therapy (in Million USD), 2025-2033
  • Table 3: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Cancer Type (in Million USD), 2025-2033
  • Table 4: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 5: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Lung Cancer Therapeutics Market: Competitive Structure
  • Table 7: Global: Lung Cancer Therapeutics Market: Key Players